Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D-CAR T cells

被引：0
|
作者：
Hu, Xiaoli [1 ]
Zhou, Xinyi [1 ]
Zhao, Qian [2 ]
Yang, Ying [1 ]
Liang, Yang [3 ]
Xiao, Yuchen [4 ]
Liu, Zhuoqun [4 ]
Liu, Liu [5 ]
Zhang, Chao [6 ]
Du, Juan [1 ]
机构：
[1] Naval Med Univ, Shanghai Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China
[2] Univ Washington, Dept Mol Biol, Seattle, WA USA
[3] Sun Yat Sen Univ, Dept Hematol Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Tongji Univ, Shanghai Yangzhi Rehabil Hosp, Fundamental Res Ctr, Shanghai Sunshine Rehabil Ctr,Sch Med, Shanghai, Peoples R China
[5] Shanghai Yuhui Pharmaceut Technol Grp Co Ltd, Shanghai, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Shanghai, Peoples R China
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 05期
基金：
中国国家自然科学基金;
关键词：
RECEPTOR;
D O I：
10.1111/bjh.19739
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2049 / 2052
页数：4
相关论文
共 50 条
  • [21] Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma
    Cao, Zhuoxiao
    Yang, Cuiqing
    Wang, Yifang
    Wang, Chao
    Wang, Qingyang
    Ye, Gang
    Liu, Tingting
    Wang, Qin
    Wang, Huanyu
    Gong, Yanxue
    Wang, Biye
    Jiang, Fuwei
    BLOOD, 2022, 140 : 7378 - 7378
  • [22] The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer
    Yan, Pengfei
    Lin, Xi
    Wu, Lijie
    Xu, Lu
    Li, Fei
    Liu, Junlin
    Xu, Fei
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [23] BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy
    Joiner, Laura
    Costa, Luciano
    Giri, Smith
    Ravi, Gayathri
    Godby, Kelly
    Hagedorn, Caitlin
    Bal, Susan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S61 - S62
  • [24] FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma
    Asher Mullard
    Nature Reviews Drug Discovery, 2023, 22 : 775 - 775
  • [25] Identification of LPAR1/LPAR5 As Novel GPCR Partners of GPRC5D for the Efficient CAR-T Therapy of Multiple Myeloma
    Zhou, Xinyi
    Yang, Ying
    Hu, Xiaoli
    Luo, Tiancheng
    Liu, Shangrun
    Zhang, Chao
    Du, Juan
    BLOOD, 2023, 142
  • [26] Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1+1 greater than 2?
    Li, Chenggong
    Mei, Heng
    LANCET HAEMATOLOGY, 2024, 11 (10): : e712 - e713
  • [27] A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma
    Tan, Yongcong
    Li, Xuezhen
    Yu, Fan
    Xu, Juehua
    Qian, Zhen
    Cao, Yiqi
    Yang, Xueyan
    Du, Qinglin
    Peng, Fei
    Han, Shuhua
    Ding, Qian
    CANCER RESEARCH, 2024, 84 (07)
  • [28] Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
    Pan, Darren
    Richter, Joshua
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2024, 19 (06) : 237 - 245
  • [29] Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody
    Chari, Ajai
    Minnema, Monique C.
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Costa, Luciano J.
    Caers, Jo
    Verona, Raluca
    Girgis, Suzette
    Yang, Shiyi
    Goldsmith, Rachel B.
    Yao, Xiang
    Pillarisetti, Kodandaram
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2232 - 2244
  • [30] DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
    Neeli, Praveen
    Maza, Perry Ayn Mayson A.
    Chai, Dafei
    Zhao, Dan
    Hoi, Xen Ping
    Chan, Keith Syson
    Young, Ken H.
    Li, Yong
    NPJ VACCINES, 2024, 9 (01)
12345